Streptococcus pneumoniae News and Research

RSS

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.

Interleukin-10 levels predict otitis media culprit

Research shows that high serum levels of interleukin-10 indicate that the likely cause of acute otitis media is infection with Streptococcus pneumoniae, as opposed to Haemophilus influenzae or Moraxella catarrhalis.

18 Feb 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

Pfizer Inc. announced today that the European Commission has approved expanding the use of the company's pneumococcal conjugate vaccine, Prevenar 13(pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae.

9 Jan 2013

Microbiologists discover how the spread of antibiotic resistance works in pneumococcus

Antibiotic resistance results from bacteria's uncanny ability to morph and adapt, outwitting pharmaceuticals that are supposed to kill them. But exactly how the bacteria acquire and spread that resistance inside individuals carrying them is not well-established for most bacterial organisms.

22 Nov 2012

Strep detection tests may miss sore throat-causing bacterial strains

Rapid streptococcal antigen detection tests, which are widely used to detect non-group A Lancefield beta-hemolytic streptococci in many developed countries, may be missing clinically important streptococci, say researchers.

19 Nov 2012

Abacus Diagnostica’s GenomEra C. difficile assay receives CE mark

Abacus Diagnostica Ltd announced that it has received the CE mark for the GenomEra C. difficile assay for the detection of toxin-producing Clostridium difficile directly from stool samples. C. difficile is the leading cause of infectious nosocomial diarrhea in Europe and North America.

19 Nov 2012

Flu virus suppresses body's ability to defend against bacteria

When infected with influenza, the body becomes an easy target for bacteria. The flu virus alters the host's immune system and compromises its capacity to effectively fight off bacterial infections. Now, a team of immunologists at the Helmholtz Centre for Infection Research (HZI) and cooperation partners has discovered that an immune system molecule called TLR7 is partly to blame. The molecule recognizes the viral genome - and then signals scavenger cells of the immune system to ingest fewer bacteria.

15 Nov 2012

New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments are urgently needed for bacterial meningitis, a devastating disease which kills or maims around a fifth of people who contract it, according to medical experts writing in a new Series on bacterial meningitis, published in The Lancet.

9 Nov 2012

Artificial CSP proteins reduce S. pneumoniae competence y more than 90%

The bacterium Streptococcus pneumoniae - which can cause pneumonia, meningitis, bacteremia and sepsis - likes to share its antibiotic-defeating weaponry with its neighbors. Individual cells can pass resistance genes to one another through a process called horizontal gene transfer, or by "transformation," the uptake of DNA from the environment.

26 Oct 2012

Thiol peroxidase involved in S. pneumoniae defenses

The Streptococcus pneumoniae bacteria defends itself from high levels of hydrogen peroxide with the help of thiol peroxidase, research shows.

22 Oct 2012

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Genocea raises $30M in Series C financing round

Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round.

10 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

Pathogens identified in majority of childhood CAP hospitalizations

A comprehensive investigation of childhood community-acquired pneumonia in Taiwan has identified at least one pathogen in 85% of previously healthy children.

10 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Aquapharm discovers new antibiotic compound against multi-drug resistant bacteria

A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.

6 Aug 2012

Pneumococcal revaccination needed in kidney transplant patients

Kidney transplant patients vaccinated against Streptococcus pneumoniae appear to be protected against pneumococcal infection for at least 15 months, research shows.

23 Jul 2012

Researchers discover HVEM’s unknown role in fighting off E. coli infections

Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.

16 Jul 2012

PCV13 offers best overall protection from CAP in young children

Researchers have identified a pneumococcal conjugate vaccine that is effective for treating bacteremic pneumococcal community-acquired pneumonia in children aged 5 years or younger.

9 Jul 2012

Polymorphism ’protective in pneumococcal disease’

Patients with invasive pneumococcal disease who have the FcyRIIa-R/R131 polymorphism may have better survival outcomes than those without the genotype, suggest study findings.

11 Jun 2012